- Gastroenterology Education and CPD for trainees and specialists - https://www.gastrotraining.com -
Colorectal cancer (CRC)
What are the clinical features of CRC?
What are synchronous and metachronous cancers?
Synchronous CRCs are defined as two or more distinct primary tumors separated by normal bowel and not due to direct extension or metastasis. It occurs in upto 5 percent of patients with colon cancer.
Metachronous CRCs are defined as non anastomotic new tumors developing at least six months after the initial diagnosis. It occurs in upto 3 percent of patients in the first five years postoperatively.
Discuss the differential diagnosis of CRC?
Rare malignancies other than adenocarcinoma which are primary to the large bowel;
Discuss the staging for CRC?
Duke’s A- Localized to the mucosa and submucosa
Duke’s B- Extending into or through the muscle layer without lymph node involvement
Duke’s C- Lymph node involvement
Duke’s D- Distant metastases
TNM staging
T1 Tumour invades the submucosa
T2 Tumour invades muscularis propria
T3 Tumor invades through the muscularis propria into the subserosa, or into non-peritonealized pericolic or perirectal tissues
T4 Tumor directly invades other organs or structures, and/or perforates visceral peritoneum
N1- Metastasis in 1-3 regional lymph nodes. N2- Metastasis in >= 4 regional lymph nodes
M0- No distant metastasis M1- Distant metastases
What investigations are needed?
Discuss the treatment of CRC?
Surgery is the only curative modality for localized colon cancer. The goal of colon cancer surgery is complete removal of the tumor along with the major vascular pedicle feeding the affected colonic segment and the lymphatic drainage basin. Regional lymphadenectomy is of prognostic and therapeutic value. At least 12 lymph nodes should be assessed for adequate staging. The 30-day postoperative mortality rate is around 5 %.
There is great variability in the frequency of postoperative bowel movements following a hemicolectomy. Most patients will have a minimal increase in frequency, and some have at least a temporary increase to four or more movements per day. Such patients may benefit from the addition of dietary fiber, and when necessary, an antimotility agent. The remaining colon will often adapt over a four to six month period, gradually returning to a more normal bowel pattern.
Laparoscopic resection is a reasonable option to open colectomy for potentially curative resection of colon cancer. Approximately 20 percent will require conversion to an open approach.
What is the role of adjuvant therapy?
Discuss the palliative options?
I. Palliation of obstruction
II. Palliation of bleeding — Unresectable bleeding tumors present difficult situation. The continued presence of the fecal stream contributes to the bleeding process. The bleeding may resolve or improve with a colonic diversion or bypass. If this fails to control the bleeding, external beam RT may be successful.
Discuss the treatment of rectal cancer?
I. Neoadjuvant therapy- Chemoradiotherapy (5-6 week course, 5-FU based) should be considered in
II. Surgery-The number of lymph nodes sampled is an important predictor of outcome. The surgical specimen should contain at least 12 lymph nodes. The criteria for unresectability are not clearly defined. Locally advanced rectal cancer is defined by some to be T3/4 or N1 disease and/or clinically bulky
There are three surgical options for rectal cancer:
III. Adjuvant therapy
In contrast to colon cancer, in which the failure pattern is predominantly distant metastases, the site of first failure in rectal cancer patients is equally distributed locally (ie, pelvis) and in distant sites (eg, liver, lung). Local recurrence is mainly related to difficulties in obtaining optimal surgical clearance of the radial margin
IV. Locally recurrent rectal cancer
The choice of therapy depends upon prior therapy and the local extent of the recurrence. Surgery or RT may permit successful salvage. Local re-radiation alone may provide palliation, but does not prolong survival
Discuss localization of rectal tumours at endoscopy?
The most reliable landmark is the dentate line, where the squamous mucosa of the anus transitions to the columnar mucosa of the rectum. The dentate line is located in the middle of the anorectal ring, which is comprised of the sphincters (internal and external). These muscles are responsible for fecal continence and usually extends 1 to 3 cm proximal to the dentate line. A tumor has to be located high enough above the top of the anorectal ring to allow for an adequate distal margin if sphincter preservation is to be achieved.
Discuss resection of colorectal cancer liver metastases?
a. Patients with extrahepatic disease that should be considered for liver resection include:
Contraindications to liver resection-
b. Normally, colorectal cancer resection & liver resection would not be performed synchronously. Lesions discovered at operation should not be biopsied. Patients with potentially resectable liver disease and who have undergone radical resection of the primary tumour should be considered for liver resection before consideration of chemotherapy. Patients with unfavourable primary pathology such as perforated primary tumour or extensive nodal involvement should be considered for adjuvant chemotherapy prior to liver resection and be restaged at three months.
c. The natural history of metastatic colorectal cancer is variable. Median survival without treatment is less than eight months from presentation but the prognosis is better for those patients with isolated hepatic metastases. However, even in the group of patients with limited metastatic liver disease, survival at five years is exceptional. Several recent large series on resection for colorectal liver metastases have reported five year survival ranging from 25% to 44%, with operative mortality of 0–6.6%.
d. It has been argued that the limiting factor to the number of lesions that can be resected is whether it is technically possible to remove all tumours. Patients with solitary, multiple and bilobar metastatic disease are candidates for liver resection. The surgeon should define the acceptable residual functioning volume, approximately one third of the standard liver volume, or the equivalent of a minimum of two segments
e. Recent data suggest that if lung metastases of colorectal origin are resectable, five year survival following thoracotomy is similar to that observed in patients after resection of colorectal liver metastases.
f. Recurrence may occur in up to 60% of patients (usually in the first 2 years) following liver resection for colorectal metastases with the most common site being in the liver. These may be suitable for re-resection. The reported morbidity and mortality rates and long term survival rates of re-resection are similar to those reported for the original hepatectomy despite the greater technical difficulty of the procedure.
g. Chemotherapy for metastatic colorectal cancer can improve survival and should be considered in all patients not suitable for surgery. NICE now recommend the use of oxaliplatin based regimens as first line therapy for all patients with non-resectable disease. There is no evidence to support ‘‘pretreatment’’ with neoadjuvant chemotherapy in patients with resectable disease.
Ref-
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com